[Nanocarrier in veterinary medicine hyperthyroidism with a nano-carrier based thiamazole ointment].

INTRODUCTION: The oral treatment of feline hyperthyroidism with antithyroid drugs often results in gastrointestinal side effects (10-20%). To date only oral formulations are approved although the oral application is not tolerated by all cats. Transdermal therapy can be an alternative. Nanocarriers could be used to ensure adequate transport of active agents through the skin. The present pilot study investigated the efficacy and safety of a novel dermal formulation of thiamazole for the treatment of feline hyperthyroidism. For the first time, amphiphilic dendritic core-multishell-nanocarriers were used. Cats with T4 values >/= 4.0 microg/dl or a T4 value from 3.0-4.0 microg/dl and defined clinical findings were recruited. The euthyroid range for the T4 value was defined from >/= 0.8 and